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BACKGROUND: Suppressive immune cells present in tumour microenvironments are known to augment tumour growth and hamper
efficacy of antitumour therapies. The amino-bisphosphonate Zoledronic acid (ZA) is considered as an antitumour agent, as recent
studies showed that ZA prolongs disease-free survival in cancer patients. The exact mechanism is a topic of debate; it has been
suggested that ZA targets tumour-associated macrophages (TAMs).
METHODS: We investigate the role of ZA on the myeloid differentiation to TAMs in murine mesothelioma in vivo and in vitro. Mice
were intraperitoneally inoculated with a lethal dose of mesothelioma tumour cells and treated with ZA to determine the effects on
myeloid differentiation and survival.
RESULTS: We show that ZA impaired myeloid differentiation. Inhibition of myeloid differentiation led to a reduction in TAMs, but the
number of immature myeloid cells with myeloid-derived suppressor cell (MDSC) characteristics was increased. In addition, ZA affects
the phenotype of macrophages leading to reduced level of TAM-associated cytokines in the tumour microenvironment.
No improvement of survival was observed.
CONCLUSION: We conclude that ZA leads to a reduction in macrophages and impairs polarisation towards an M2 phenotype, but this
was associated with an increase in the number of immature myeloid cells, which might diminish the effects of ZA on survival.
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Recently, cancer-related inflammation was recognised as the seventh
hallmark of cancer (Colotta et al, 2009). Infiltration of inflammatory
cells into tumour tissues can be detected in many cancers.
These infiltrating immune cells can possess immune stimulatory
(antitumour activity) or immune suppressive capacity and thus
promote tumour progression. In the tumour microenvironment of a
progressing tumour, regulatory T cells, myeloid-derived suppressor
cells (MDSCs) and tumour-associated macrophages (TAMs) have an
important role in facilitating tumour growth and immune escape by
suppressing antitumour effector cells (Bronte et al, 2001; Hegmans
et al, 2006; Sakaguchi et al,2 0 0 8 ;S i c aet al, 2008; Allavena et al,
2008b; Gabrilovich and Nagaraj, 2009).
Regulatory T cells and MDSCs are regarded as immune
suppressive, as they are capable of inducing T-cell apoptosis and
T-cell tolerance (Nagaraj and Gabrilovich, 2007; Sakaguchi et al,
2009), whereas TAMs are involved in a variety of processes,
including angiogenesis, tumour invasion and tumour metastasis
(Pollard, 2004; Condeelis and Pollard, 2006). Tumour-associated
macrophages are derived from circulating monocytic precursors.
Recently, it has been shown that this group of immature myeloid
cells can be derived in three different populations, carrying
MDSC characteristics, and can also function as a pool of precursor
cells for macrophages and endothelial cells. Mononuclear-MDSC
(MO-MDSC) harbours immune suppressive capacities, but
additionally function as TAM precursors, in contrast to poly-
morph nuclear-MDSC (PMN-MDSC) and CD11b
highGr-1
low-MDSC
(Bronte and Zanovello, 2005; Nagaraj and Gabrilovich, 2007;
Gabrilovich and Nagaraj, 2009; Greifenberg et al, 2009).
Tumour-associated macrophages acquire a polarised phenotype
of alternatively activated macrophages (M2), whereas classically
activated macrophages (M1) are more associated with inflamma-
tion. These two types of macrophages differ in receptor expression,
effector function, and cytokine and chemokine productions
(Mantovani et al, 2002). By producing pro-angiogenic enzymes,
like matrix metalloproteinase 9 (MMP-9), TAMs are able to break-
down the extracellular matrix, leading to the release of pro-angio-
genic proteins and growth factors. In addition, TAMs produce
vascular endothelial growth factor (VEGF), promoting angiogen-
esis and recruitment of cells derived from the myeloid lineage
(Kusmartsev and Gabrilovich, 2002; Siveen and Kuttan, 2009).
The recruitment of immature myeloid cells is enhanced by the
production of chemokine (C–C motif) ligand-2/monocyte-chemo-
tactic protein-1 (CCL-2/MCP-1), which is produced and expressed
by TAMs and tumour cells. Within the heterogeneous group of
immature myeloid cells, subpopulations are defined, which can
further differentiate into mature macrophages, and hence TAMs
provide their own precursor cells, which enhances tumour
progression (Rossner et al, 2005; Umemura et al, 2008; Greifenberg
et al, 2009; Dolcetti et al, 2010).
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progression, thereby enhancing antitumour therapies. Bispho-
sphonates have been reported to target macrophages. They were
initially prescribed to improve bone density; however, in
metastasing cancers, a possible role in prevention of metastasis
and prolongation of disease-free survival has been described (Diel
et al, 2000, 2008; Gnant et al, 2009). The exact mechanisms by
which bisphosphonates prevent disease progression are still a topic
of extensive investigations. It has been proposed that bisphos-
phonates have a direct apoptotic effect on tumour cells (Yoneda
et al, 2000; Mundy, 2001, 2002; Fromigue et al, 2003). In addition,
indirect effects of bisphosphonates have been reported. It has been
suggested that bisphosphonates modulate the immune response
and may influence macrophage phenotype (Wolf et al, 2006;
Tsagozis et al, 2008; Coscia et al, 2009).
Currently, we are investigating novel therapeutic strategies in
mesothelioma, like dendritic cell-based immunotherapy. Meso-
thelioma is a cancer with dismal prognosis deriving from the layers
of the pleural cavity or the peritoneal cavity. As high numbers of
TAMs are found in pleural effusions and tumour biopsies in human
mesothelioma, we determined the efficacy of a bisphosphonate,
Zolendric acid (ZA) (Zometa; Novartis Pharma BV, Arnhem, The
Netherlands), on TAM formation and tumour progression in a
murine mesothelioma model.
In this study, we analysed the effect of ZA on myeloid differen-
tiation both in vitro and in vivo. In addition, we determined
whether ZA changed the phenotype of macrophages. Animal
studies were performed to investigate the effect of ZA on survival.
METHODS
Animals and cell lines
CBA-j mice (specific pathogen free, female, 6–8 weeks old) were
purchased from Harlan (Huntington, UK) and were housed under
pathogen-free conditions at the Erasmus MC animal facility. All
experiments were approved by the local ethical committee for
animal welfare (Erasmus University Committee of Animal Experts,
Rotterdam, the Netherlands) and complied with the guidelines for
the welfare of animals in experimental neoplasia by the United
Kingdom Coordinating Committee on Cancer Research (UKCCCR)
and by the Code of Practice of the Dutch Veterinarian Inspection.
The AC29 cell line is kindly provided by Professor BWS Robinson
(School of Medicine and Pharmacology, Sir Charles Gairdner
Hospital Unit, The University of Western Australia, Perth,
Australia).
Depletion of macrophages in vivo
Macrophages were depleted by intraperitoneal (i.p.) injection of
liposome-encapsulated clodronate (Dr Nico Van Rooijen, VUmc,
FdG, Amsterdams, The Netherlands) (Claassen, 1992; Van Rooijen
and Sanders, 1994).
CBA-j mice were i.p. inoculated with a lethal dose of 20 10
6
AC29 tumour cells on day 0. Mice were i.p. injected with 200ml
liposome-encapsulated clodronate or liposome-encapsulated PBS
at days 5 and 10 after tumour injection. At day 12 mice were killed
using CO2. The peritoneal cavity of tumour-bearing mice was
washed with 1ml PBS to obtain peritoneal cells for FACS analysis.
All visible tumour material was excised from each mouse and data
are expressed as wet weight (accuracy of 0.001g).
Tumour-associated macrophages were defined by the expression of
F 4 / 8 0 ,M H C I Ia n dC D 2 0 6( m a r k e rf o rM 2m a c r o p h a g ep h e n o t y p e ) .
Immunohistochemistry on tumour biopsies
Tumour material was obtained 25 days after tumour injection from
the peritoneal cavity of tumour-bearing mice. Tumour biopsies
were embedded in Tissue-Tek II optimum cutting temperature
medium (Miles, Naperville, IL, USA), snap frozen in liquid
nitrogen and stored at  801C. Tissue sections (6mm) were cut
in an HM-560 cryostat (Microm, Heidelberg, Germany). F4/80
(Dr L Boon, Bioceros, Utrecht, The Netherlands) and CD206
(Serotec, Oxford, UK) primary antibodies were incubated for
1h at room temperature. Binding of antibodies was detected using
the immunoalkaline phosphatase antialkaline phosphatase
method (DAKO, Glostrup, Denmark). Naphthol-AS-MX-phos-
phate (0.30mgml
 1; Sigma-Aldrich Chemie BV, Zwijndrecht,
The Netherlands) and new fuchsine (160mgml
 1 in 2 M HCl;
Chroma-Gesellschaft, Ko ¨ngen, Germany) were used as substrate.
The specificity of the antibodies was checked using a protein
concentration-matched non-relevant monoclonal antibody and PBS.
Flow cytometry
Spleens were aseptically removed and mechanically dispersed in
cold PBS. Cell suspensions were filtered through a 100-mm nylon
cell strainer (BD Biosciences, Bedford, MA, USA), depleted of
erythrocytes by osmotic shock, washed twice in RPMI and adjusted
to a concentration of 1 10
6 cellsml
 1 in FACS buffer.
Splenocytes were stained with the following monoclonal
antibodies: Ly6C (FITC), F4/80 (FITC), MHCII (PE), CD11c
(PE-Texas red), CD11b (PerCP-Cy5.5), CD31 (PE-Cy7), CD206
(Alexa 647), Ly6G (Alexa Fluor 700), Gr-1 (APC-Cy7) and a fixable
live/dead marker in DAPI (Invitrogen, Breda, The Netherlands).
The final analysis and graphical output were performed using
FlowJo software (Tree Star Inc., Costa Mesa, CA, USA).
Macrophage culture
Single-cell suspensions of bone marrow, isolated from femurs and
tibias of naı ¨ve mice, were cultured in RPMI supplemented with
10% foetal calf serum, 2.5ml gentamicin (10mgml
 1) (Gibco,
Breda, the Netherlands) and b-mercaptoethanol (Sigma-Alderich)
(further referred to as culture medium).
Bone marrow cells were isolated from the femurs and tibias of
naı ¨ve mice under sterile conditions (Inaba et al, 1992). In short, all
muscle tissues are removed with gauze from the bones and placed
in a 60-mm dish with 70% alcohol for 1min, washed twice with
PBS and transferred into a fresh dish with RPMI 1640. Both ends of
the bones were cut with scissors in the dish, and then the marrow
was flushed out using 2ml of RPMI 1640 with a syringe and
25-gauge needle. The tissue was suspended, passed through nylon
mesh to remove small pieces of bone and debris, and red cells were
lysed with ammonium chloride. A concentration of 10ngml
 1
M-CSF (R&D systems, Oxon, UK) was used in our bone marrow
cultures according to the protocol of Wan et al (2007, 2009))
or 30% tumour supernatant from AC29 cell culture (at 80%
confluency) was added on day 0 to a culture of 2 10
6 bone
marrow-derived cells. AC29 was cultured in RPMI-1640 (Gibco,
Paisley, UK) supplemented with GlutaMax, 10mM HEPES and 5%
heat-inactivated foetal bovine serum. When confluency reached
80% (typically 3–4 days), supernatant was collected, centrifuged
for 10min at 1000g to remove cells/cell debris. Supernatant
is added to the bone marrow culture at a concentration of 30%.
This concentration was selected based on findings by Tsagozis et al
(2008), who described that 30% tumour supernatant generated
macrophages with a characteristic TAM phenotype. Zoledronic acid
(ZA) (Zometa, Novartis Pharma BV) was added on day 0 to the
culture conditions in different concentrations: 0.03, 0.15 or 0.3mM.
All culture experiments have been repeated five times under
comparable conditions.
Mononuclear-MDSCs were isolated from the spleen of tumour-
bearing mice. Four to six colour samples were sorted using a
FACSAria equipped with FACSDIVA software (BD Biosciences).
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experiment has been repeated twice under comparable conditions.
Zoledronic acid treatment protocol
CBA-j mice were divided into two groups: each group consisting of
10 mice. On day 0, all mice were i.p. injected with a lethal dose of
20 10
6 AC29 tumour cells. One group was treated daily with
subcutaneous (s.c.) ZA injections (100mgkg
 1, B2.5mg per mice)
in 100ml PBS and the other group was treated with 100ml PBS as a
control starting at day 5. This dosage was proven effective and
non-toxic in mice (Stathopoulos et al, 2008).
Of both groups, five mice were killed at day 25. The others were
killed when found profoundly ill. The occurrence of tumour
growth, body weight, physical well-being and survival were
measured for 2 months as described previously (Hegmans et al,
2005). Survival experiments were repeated three times under
comparable conditions.
Enzyme-linked immunosorbent assay
To measure cytokine levels, effusion fluid from the peritoneal
cavity of tumour-bearing mice was obtained at day 25 after tumour
injection. IL-10, IL-12, TNFa, IL-6, IL-1b, CCL-2 (MCP-1) and
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Figure 1 Depletion of macrophages inhibits tumour development. On day 1, mice were i.p. injected with a lethal dose of AC29 mesothelioma tumour
cells and were treated twice with liposome-encapsulated clodronate (macrophage depletion) or liposome-encapsulated PBS (control) on days 5 and
10 after tumour injection (n¼10). Twelve days after tumour injection, mice were killed and tumour weight was measured. All visible tumour material was
excised from each mouse and data are expressed as wet weight (accuracy of 0.001g). FACS analysis was performed to verify the effectiveness of
macrophage depletion using liposome-encapsulated clodronate. Tumour biopsies were embedded in Tissue-Tek II and snap frozen in liquid nitrogen. Tissue
sections (6mm) were analysed for the presence of macrophages. (A) Effect of macrophage depletion on tumour growth. Tumour growth was observed in
all five mice treated with control liposomes; in contrast, only two out of five mice treated with macrophage-depleting liposomes developed visible tumour
growth on day 12. Significant reduction in the percentage of F4/80
þMHCII
þ cells was found in the peritoneal cavity of macrophage-depleted mice
(P¼0.0015). Tumour weight was found to be lower in macrophage-depleted animals (P¼0.077). (B) TAMs in murine mesothelioma. Tumour biopsies
of control-treated mice showed infiltration of F4/80
þ and CD206
þ cells (magnification: upper,  200; lower,  400). **Po0.001.
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ELISA assay (IL-10, IL-12 and TNFa: R&D systems, Abingdon, UK;
IL-6, IL-1b and CCL-2 (MCP-1): BD Biosciences; VEGF: Calbio-
chem, Darmstadt, Germany). Protocols were followed as per the
manufacturer’s instructions. Samples were diluted appropriately to
ensure that readings were within the limits of accurate detection.
Results are expressed as pgml
 1 of effusion fluid.
Statistical analysis
Data are expressed as mean±s.d. Comparisons between groups
were made using t-tests. A two-tailed P-value o0.05 was
considered significant. Data presented as a percentage of
tumour-free animals were analysed with Kaplan–Meier survival
curves, using the log-rank test to determine significance.
RESULTS
Macrophages are essential in the onset and tumour
development
We investigated the effect of the depletion of macrophages on
tumour progression in a murine model for mesothelioma by
treating mice with liposome-encapsulated clodronate. These
liposomes are readily taken up by phagocytic cells, including
macrophages, and induce cell-specific apoptosis after clodronate is
set free into the cytoplasm of cells (Claassen, 1992; Van Rooijen
and Sanders, 1994).
Mice were i.p. inoculated with a lethal dose of AC29 tumour cells
and mice were treated with liposome-encapsulated clodronate
or liposome-encapsulated PBS on days 5 and 10 after tumour
injection. Mice were killed 12 days after tumour injection. All
visible tumour material was excised from each mouse and wet
weight was measured (accuracy of 0.001g. FACS analysis was
performed to verify the effectiveness of macrophage depletion
(Mantovani et al, 2002; Sica et al, 2006).
Treatment with liposome-encapsulated clodronate significantly
reduced the number of macrophages in the peritoneal cavity of
tumour inoculated mice (P¼0.0015). All mice (n¼5) treated with
liposome-encapsulated PBS showed profound tumour growth at
day 12. Three of the five mice treated with liposome-encapsulated
clodronate had no visible tumour. In the case of mice that did
develop tumour, tumour growth was less profound (Figure 1A).
Macrophages (M1/M2) were found scattered throughout the
tumour of a control mice (Figure 1B).
These data show that macrophages have a significant role in the
onset and progression of tumour in our murine mesothelioma
model.
Zoledonic acid inhibits myeloid differentiation in vitro
To investigate the effect of ZA on myeloid differentiation in vitro,
total bone marrow cells were cultured with M-CSF or 30% tumour
supernatant in the presence or absence of ZA for 6 days using
similar culture conditions as described by others (Wan et al, 2007,
2009; Tsagozis et al, 2008). FACS analysis was performed daily. ZA
was added in different concentrations: 0.03, 0.15 or 0.30mM.
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Figure 2 ZA inhibits differentiation of myeloid cells in vitro. The effect of ZA on myeloid differentiation was determined by cultured bone marrow-derived
cells with 0.5mgml
 1 M-CSF or RPMI containing 30% tumour supernatant. Cells were cultured for 6 days. ZA was added to the cultures on day 0 in different
concentrations (0.03, 0.15 or 0.30mM). FACS analysis was performed daily. ZA inhibits the downregulation of Gr-1
þ cells and the upregulation of F4/80
þ
and MHCII
þ cells in a dose-dependent manner. Experiments were repeated and data of five individual experiments were then combined. No significant
differences were observed in the number of cells between the different culture conditions. A significant difference was found in the percentage of immature
myeloid cells and the percentage of macrophages after 6 days of culture in both, resulting in a higher number of immature cells and a lower number
of macrophages in ZA culture conditions. (A) Bone marrow culture with M-CSF: immature myeloid cells, *P¼0.004; **P¼0.0001; ***Po0.0001;
macrophages, *P¼0.0003; **Po0.0001; ***P¼0.005. (B) Bone marrow culture with 30% tumour supernatant: immature myeloid cells, *P¼0.016;
**P¼0.0014; ***P¼0.0025; *00P¼0.015; **00P¼0.036; macrophages, *P¼0.002; **P¼0.0011; ***P¼0.006; *00P¼0.0004, **00P¼0.001.
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Figure 3 ZA inhibits the upregulation of extracellular markers in vitro. Expression profiles of M-CSF and RPMI containing 30% tumour supernatant
cultured cells were measured by FACS to determine the effect of ZA addition to the culture (0.5mgml
 1 M-CSF; 0.30mM ZA was added on day 0). CD206
on macrophages was analysed to determine changes in macrophage phenotype. (A) M-CSF culture. F4/80, CD11c and MHCII were upregulated within 6
days. The immature myeloid marker Gr-1 was rapidly downregulated. The addition of ZA to the culture supernatant reduced the upregulation F4/80 and
MHCII and CD11c, leading to a significant difference in MFI of these markers on day 6 of culture (P¼0.003, 0.0023, 0.0003, respectively). As a consequence,
the expression of Gr-1 was still high in a majority of the cells after 6 days of culture. (B) CD206 expression on macrophages (M-CSF culture and 30%
tumour supernatant culture). After day 5, almost all F4/80
þMHCII
þ cells in the M-CSF culture expressed CD206. The upregulation of CD206 on cells
cultured in the presence of tumour supernatant was more explicit. The addition of ZA to the cultures reduced the expression of CD206 on macrophages in
both conditions and a significant reduction in the MFI of CD206 on macrophages after 6 days of culture (Po0.0001). Experiments were repeated several
times under comparable conditions (n¼5). Determination of the significance of peak shifts was based on calculation of the MFI.
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number of cells expressing the immature marker Gr-1; however,
the downregulation of Gr-1 was delayed when ZA was added to
the culture. Simultaneously, a delay in the upregulation of
macrophage markers was observed when ZA was added. The
delay in the downregulation of Gr-1 and the upregulation of
F4/80 and MHCII was dose dependent, leading to a reduced
number of mature macrophages after 6 days of culture when
ZA was added to the culture (Figure 2). The total number of
cells within the different culture conditions did not significantly
change over time.
To summarise, we observed an inhibition of myeloid differen-
tiation to macrophages when ZA was added to the culture
conditioned for macrophages. This inhibitory effect on differentia-
tion was dose dependent and led to significant differences in the
number of macrophages and immature cells between the different
culture conditions on day 6. Furthermore, we showed that tumour-
derived factors present in tumour supernatant induced the
development of macrophages from bone marrow-derived cells.
Zoledronic acid shifts the balance from M2 macrophages to
M1 macrophages in vitro
To investigate the influence of ZA on the differentiation of myeloid
progenitor cells to macrophage phenotypes, bone marrow cells
were cultured in the presence or absence of 0.30mM ZA. Cells were
cultured with M-CSF or 30% tumour supernatant as described
previously (Wan et al, 2007, 2009; Tsagozis et al, 2008). The
mannose receptor CD206 is a specific marker for M2 macrophages;
therefore, the expression of this marker was analysed during
culture to observe changes in macrophage phenotype (Mantovani
et al, 2002).
Both M-CSF and 30% tumour supernatant culture conditions
revealed that macrophage markers, F4/80, CD11c and MHCII, were
rapidly upregulated within 6 days of culture. Simultaneously, the
marker for immature myeloid cells Gr-1 was downregulated.
However, the addition of ZA to the culture significantly inhibits
the upregulation of F4/80, MHCII and especially CD11c, leading to
a significant difference in mean fluorescent intensity (MFI) of
these markers on day 6 of culture (P¼0.003, 0.0023 and 0.0003,
respectively). The expression of Gr-1 remained high in both these
culture conditions (Figure 3A).
On day 1, cells expressed CD206 at low levels; however, at day 2
of culture, a slight increase was found in both conditions. This
upregulation persisted in the following days in the M-CSF culture
conditions. In those conditions where ZA was added to the M-CSF
culture, the upregulation of CD206 was abolished. The upregula-
tion of CD206 took place earlier in the tumour supernatant
conditions compared with the M-CSF culture. As a consequence,
the blocking effect of ZA on the generation of M2 macrophages
was more profound, leading to a complete inhibition in the
upregulation of CD206 by ZA and a significant reduction in the
MFI of CD206 on macrophages after 6 days of culture (Po0.0001)
(Figure 3B).
In conclusion, these data showed that the addition of ZA to
macrophage-inducing culture conditions significantly inhibits the
upregulation of F4/80, MHCII and CD11c. In addition, these data
reveal that addition of tumour supernatant leads to polarisation of
the macrophage phenotype towards M2, and that ZA can prevent
this polarisation in vitro, leading to a significant reduction in the
MFI of CD206 on macrophages cultured in the presence of ZA
(Po0.0001).
Zoledronic acid does not improve survival in a murine
tumour model
Next, we investigated whether treatment with ZA had an effect on
survival. Mice were i.p. inoculated with AC29 tumour cells and
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Figure 4 Treatment with ZA does not improve survival. Mice were
divided into two groups (n¼10 mice per group). Mice were treated daily
with s.c. ZA (100mgkg
 1, B2.5mg per mice) or PBS injections starting on
day 5 after tumour injection. This dosing schedule was proven effective and
non-toxic (Stathopoulos et al, 2008). Mice were killed when found
profoundly ill. No significant improvement of survival was measured.
(A) Kaplan–Meier survival curve. No significant differences in survival were
observed between mice treated daily with s.c. injection of ZA compared
with untreated mice (P¼0.3675). (B) Malignant effusions and tumour
weights. Tumour weight and the amount of malignant effusion were
measured when mice were killed. The effusion fluid was removed from the
peritoneal cavity by fine-needle aspiration and all visible tumour material
was collected. No significant differences in tumour weight or the amount of
malignant effusion were observed (P¼0.42 and 0.61). (C) Myeloid cell
types in the spleen of tumour-bearing mice. Long-term treatment effects
were observed in the number of myeloid cells within the spleen of tumour-
bearing mice, implicating that higher numbers of myeloid precursors and
lower numbers of TAMs were detected in mice treated with ZA compared
with untreated mice.
Zoledronic acid impairs myeloid differentiation
JD Veltman et al
634
British Journal of Cancer (2010) 103(5), 629–641 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
streated daily with s.c. ZA injections or PBS as a control. The dosing
schedule was chosen according to the literature, in which it was
proven effective and non-toxic (Stathopoulos et al, 2008). Mice
were weighted on a daily basis and killed when found profoundly
ill. The effusion fluid was collected when mice were killed.
No significant prolongation of survival was observed upon
treatment with ZA (P¼0.2183) (Figure 4A). No significant
differences were found in the total body weight or in the amount
of effusion fluid volume during the experiment (P¼0.4178 and
0.6103, respectively) (Figure 4B). Long-term treatment effects
showed that higher numbers of myeloid precursors and lower
numbers of TAMs were detected in mice treated with ZA compared
with untreated mice; however, no effects were found in tumour
burden and survival (Figure 4C).
Taken together, although no significant differences on tumour
progression and survival could be observed between untreated
mice and mice treated with ZA, a reduction in the number of
macrophages and an increase in the number of immature myeloid
cells was detected.
Identification of myeloid cells in vivo
To establish whether ZA inhibits myeloid differentiation in
tumour-bearing mice, myeloid cell types within the spleen, tumour
and peritoneal cavity of tumour-bearing mice were identified.
Recently, it has been shown that the heterogeneous group of MDSC
consists of three major groups: polymorph nuclei CD11b
highGr-
1
high MDSC (PMN-MDSC), mononuclear CD11b
highGr-1
int MDSC
(MO-MDSC) and the CD11b
highGr-1
low-MDSC (Greifenberg et al,
2009). Identification of MDSC subtypes was carried out on cells of
untreated tumour-bearing mice 25 days after tumour inoculation.
The population of PMN-MDSC produces high levels of reactive
oxygen species leading to the downregulation of the z-chain of
T cells, resulting in T-cell tolerance, whereas MO-MDSC can
directly inhibit T-cell expansion by the production of nitric oxide-
inducing T-cell apoptosis (Bronte and Zanovello, 2005; Nagaraj
and Gabrilovich, 2007; Gabrilovich and Nagaraj, 2009).
A massive increase in MDSC was found in the spleens and
effusion fluids from the peritoneal cavity of tumour-bearing mice
on day 25 after tumour injection. MDSCs were further subdivided
into three groups: PMN-MDSC, MO-MDSC and Gr-1
low-MDSC.
All subgroups of MDSC stained intermediate positive for the
marker CD206 (Figure 5A). Expression of the markers F4/80 and
MHCII was found on MO-MDSC and Gr-1
low-MDSC, but not on
PMN-MDSC. A small subpopulation of the MO-MDSC was
strongly positive for F4/80, MHCII and CD206 (Figure 5A).
In the peritoneal cavity and in the spleen, M1 and M2 macro-
phages were identified based on the expression of F4/80, MHCII
and CD206, and forward–sideward scatter patron. M2 macro-
phages express higher levels of CD206 and F4/80 and lower levels
of MHCII compared with the M1 macrophage population
(Figure 5B).
New insights have revealed that MO-MDSC are pluripotent and
under certain conditions are able to differentiate into TAMs
(Rossner et al, 2005; Umemura et al, 2008; Greifenberg et al, 2009;
Dolcetti et al, 2010). This is also reflected in vivo, as the population
of MO-MDSC already showed partial expression of F4/80 and
MHCII in an early stage compared with PMN-MDSC. To confirm
that MO-MDSC could further differentiate into macrophages,
we sorted this population from the spleen of tumour-bearing mice
and cultured the cells for 5 days in the presence of M-CSF.
Mononuclear-MDSC upregulated the expression of F4/80 and
MHCII rapidly, in contrast to the PMN-MDSC that were not able to
upregulate F4/80 under the influence of M-CSF (Figure 5C).
To summarise, we were able to identify three populations of
MDSC as described in the literature in our tumour model. The
MO-MDSCs were found to be able to differentiate into macro-
phages. Two populations of macrophages based on CD206
expression were found both in the spleen and in the peritoneal
cavity of tumour-bearing mice.
Zoledronic acid reduces macrophages but increases the
number of immature myeloid cells during tumour
development
As we observed a difference in the number of macrophages and
immature myeloid cells during ZA treatment, we next wanted to
know whether ZA treatment also affects macrophage phenotype in
vivo. To investigate whether ZA influences the development of
macrophages during tumour progression in vivo, mice were i.p.
inoculated with AC29 tumour cells and treated daily with s.c. ZA
injections (100mgkg
 1, B2.5mg per mice) or PBS as a control.
Mice were killed 25 days after tumour injection.
An increase in CD11b
þGr-1
þ cells was found in the spleen and
effusion fluid of tumour-bearing mice of both groups. A significant
increase was found in MO-MDSC both in the spleen and in the
effusion fluid from the peritoneal cavity (spleen: P¼0.0312;
effusion fluid: P¼0.034), whereas no significant differences were
found in the proportion of PMN-MDSC and Gr-1
low-MDSC
(spleen: P¼0.77 and 0.75; effusion fluid: P¼0.74 and 0.72). The
proportion of macrophages in the spleen of ZA-treated mice was
significantly lower compared with PBS-treated mice (P¼0.0091).
There was a trend towards a shift in macrophage phenotype from
M2 to M1; however, the reduction in M2 macrophages was not
significant (P¼0.18). However, we found that the expression levels
of CD206, expressed as the MFI, were significantly lower on M2
macrophages of ZA-treated mice compared with M2 macrophages
in the spleen of PBS-treated mice (P¼0.0095) (Figure 6A). No
significant decrease was found in the percentage of macrophages
in the effusion fluid of ZA-treated mice (P¼0.75). However, a
significant increase in M1 macrophages was found, while M2
macrophages were reduced (P¼0.035 and 0.33). A shift from M2
macrophage to M1 macrophage phenotype was found based on the
MFI expression of CD206, confirming the findings in the spleen
(P¼0.14). As a result, a difference in ratio of M1:M2 was found
(P¼0.011) (Figure 6B).
Enzyme-linked immunosorbent assay on the effusion fluid
was performed to determine whether the reduction on CD206
expression on macrophages in ZA-treated mice was accompanied
by changes in cytokine, chemokine and growth factor production.
A significant increase was found in the levels of IL-6, IL-12 and
IL-1b in the effusion fluid of ZA-treated mice (P¼0.049, 0.042
and 0.005, respectively). In addition, we observed a significant
reduction in VEGF and CCL-2 (MCP-1) in the effusion fluid of
ZA-treated animals (P¼0.05 and 0.039). Levels of IL-10 and TNFa
were not detectable in the effusion fluid.
In conclusion, we have shown that treatment with ZA reduces
the number of macrophages, but at the same time, we observed
higher levels of immature myeloid cell types. When we further
defined the population of immature myeloid cells, significantly
more MO-MDSC were found. In addition, we found that the
expression of CD206 on macrophages was lower in ZA-treated
animals. This reduced expression of the M2 macrophages marker
was accompanied with a significant reduction in VEGF and CCL-2
(MCP-1) levels and a significant increase in the levels of IL-6, IL-12
and IL-1b (Figure 6C).
DISCUSSION
Many effects of bisphosphonates have been reported in literature.
Treatment with ZA prolongs the 1-year survival rate in breast
cancer, prostate cancer and bladder cancer (Gnant, 2009; Rajpar
et al, 2010; Zaghloul et al, 2010). However, exact mechanisms by
which ZA prevents disease progression is still a topic of
investigation. The role of bone formation and mineralisation in
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srelation to adhesion and tumour outgrowth in these structures has
gained interest after treatment with bisphosphonates appear to
have protective effects on the prevention of bone metastasis
(Boissier et al, 1997, 2000; Magnetto et al, 1999; Montague et al,
2004). Besides the reduction in bone metastasis, studies have
shown that ZA also prevents metastasis to secondary organs
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s(Hiraga et al, 2004). Therefore, other mechanisms, during tumour
progression, may be influenced by ZA treatment. Recently, it has
been suggested that ZA may work as immune modulator and may
therefore be applicable as and antitumour agent (Clezardin, 2005;
Tsagozis et al, 2008; Santini et al, 2010).
ZA is an aminobisphosphonate that targets the mevalonate
pathway in myeloid cells (Wolf et al, 2006). Recently, several
clinical trails have been performed to investigate the role of ZA in
tumour progression (Saad et al, 2002, 2004; Gainford et al, 2005). It
has been suggested that ZA has direct antineoplastic activity on
tumour cells (Santini et al, 2003; Clezardin, 2005; Ohtsuka et al,
2005; Caraglia et al, 2007). However, other studies have shown that
clinically observed effects of ZA treatment may also be explained
by indirect mechanisms involving immune modulation.
Studies have shown that ZA eventually leads to stimulation and
proliferation of gamma/delta T cells (Kunzmann et al, 2000;
Miyagawa et al, 2001; Sato et al, 2005). Besides, direct effects of ZA
on tumour cell have been reported in breast cancer, prostate and
bladder cancer (Gnant et al, 2009; Rajpar et al, 2010; Zaghloul et al,
2010). However, more recently the effect of ZA on macrophages
has gained interest. Macrophages are known to have a dominant
role within the tumour microenvironment. Several studies have
reported the importance of TAMs on tumour progression (Pollard,
2004; Sica et al, 2006, 2008; Sangaletti et al, 2008; Allavena et al,
2008b; Coffelt et al, 2009). We and others have shown that
depleting TAMs with liposome-encapsulated clodronate inhibits
tumour growth and prolongs survival (Zeisberger et al, 2006;
Miselis et al, 2008).
As our in vitro data revealed that ZA inhibits the differentiation
towards macrophages, our aim was to determine whether this
inhibition in differentiation also led to a reduction in TAMs
in vivo.
The percentage of macrophages in the spleen was significantly
reduced in ZA-treated animals compared with the control group.
In the effusion fluid, no significant difference was found in the
total number of macrophages; however, a shift towards a more M1
macrophage phenotype was observed. Recent studies have shown
that TAMs can be derived from certain subpopulations within the
heterogeneous MDSC population (Rossner et al, 2005; Umemura
et al, 2008; Greifenberg et al, 2009; Dolcetti et al, 2010). From
these studies, it has been established that TAMs were mainly
derived from the MO-MDSC population. A significant increase in
MO-MDSC was found both in the spleen and in the effusion fluid
of mice treated with ZA. As we found that ZA inhibits myeloid
differentiation in vitro, it can be assumed that the significant
increase in the MO-MDSC population found in ZA-treated mice
compared with untreated mice are caused by similar inhibitory
effects on myeloid differentiation. Inhibition of myeloid differen-
tiation by ZA has also been reported by others (Wolf et al, 2006;
Melani et al, 2007; Chen et al, 2009).
Tsagozis et al (2008) reported that ZA shifts TAMs from an
M2-like phenotype to an M1-like phenotype, resulting in a reduc-
tion in TAM-associated cytokine production in vitro. We were able
to confirm these data in vitro, but were also able to show that these
changes also occur in vivo. A reduction in the M2-associated
receptor (CD206) was found on macrophages in tumour-bearing
mice treated with ZA. Changes in M2-associated cytokines,
chemokines and growth factors were observed in the effusion
fluid after ZA treatment. We showed that ZA lowered the levels
of VEGF in the effusion fluid of tumour-bearing mice. The reduc-
tion in VEGF and MMP-9 expressions by macrophages under the
influence of ZA has been described to prevent tumour neovascu-
larisation (Santini et al, 2002; Giraudo et al, 2004; Vincenzi et al,
2005; Melani et al, 2007; Tsagozis et al, 2008). The production of
MMPs and VEGF is known to be essential during tumour
progression and especially facilitating metastases (Allavena et al,
2008b; Coffelt et al, 2009).
Even though it was found that ZA inhibits myeloid differentia-
tion and shifts the balance from M2 macrophage phenotype
towards an M1 macrophage phenotype, this did not improve
survival in our model. There are several explanations for this
finding. One of the most striking findings was the increased levels
of immature myeloid cells (MDSC) due to treatment with ZA.
Recently, studies have reported the role of MDSC in tumour
progression. MDSC are most known for their immune suppressive
function and induction of tumour-specific T-cell tolerance
facilitating tumour immune escape (Bronte and Zanovello, 2005;
Nagaraj and Gabrilovich, 2007; Gabrilovich and Nagaraj, 2009).
Therefore, the inhibition of myeloid development may lead to
reduction in the number of TAMs, resulting in a higher number
of MDSC, which also promote tumour progression.
A second reason as to why ZA has no effect on survival may be
assigned to the shift in macrophage phenotype. As most studies
showed that TAMs are polarised to an M2 phenotype that
contribute to carcinogenesis, shifting the phenotype of macro-
phages to M1 seems promising. M1 macrophages produce less
tumour growth-promoting soluble factors and can potentially kill
tumour cells. However, the question rises whether shifting the
phenotype in full-blown tumours is possible and whether
repolarisation is as promising as believed previously (Mills et al,
1992; Mantovani et al, 2002; Weigert and Brune, 2008). Negative
aspects of iNOSþ M1 macrophages were also observed. Actually,
these cells can kill tumour cells, but as a consequence pro-
carcinogenic substances are released from dying cells, leading to
enhanced angiogenesis and enhanced polarisation of M1 macro-
phages to an M2 phenotype (Weigert and Brune, 2008). Coscia
et al. reported similar observation. In their study, repolarisation of
the macrophage phenotype was most promising during early
tumour development, resulting in prolonged tumour-free survival
and overall survival. In addition, they notify that shifting the
phenotype in a host with a large tumour burden can be hazardous
and no effects of ZA administration were observed when in situ
carcinomas had progressed. From their data, it appears that
tumour development is inhibited when the induction of M2
macrophages can be post-poned. We observed similar findings:
shifting the phenotype from M2 to M1 at later stages of
tumourigenesis seems less effective. Therefore, it can be hypothe-
sised that preventing the formation of M2 macrophages is a critical
key in preventing tumour outgrowth during early stages of disease
development.
A third explanation for the limited effect on survival could be
that ZA has effects on processes during tumour development that
Figure 5 Identification of myeloid cells in tumour-bearing mice. To identify the effect of tumour growth on the recruitment of myeloid cells during tumour
progression, mice were inoculated with tumour cells and killed on day 25 (n¼12). (A) Identification of myeloid cell types in splenocytes of tumour-bearing
mice. Immature myeloid cells could be divided into three groups, as described in the literature (Greifenberg et al, 2009). The Gr-1
low-MDSC showed
intermediate expression of F4/80, MHCII and CD206. F4/80 expression was found in MO-MDSC, but not in PMN-MDSC. A small number of MO-MDSC
expressed high levels of F4/80 MHCII and CD206. MHCII and CD206 expressions were low in PMN-MDSC. (B) Identification of type I and type II
macrophages in splenocytes of tumour-bearing mice. Two populations of macrophages could be identified; a high expression of CD206 was found in the
membrane of the population with a high expression of F4/80 but lower expression of MHCII. (C) M-CSF culture of MO-MDSC-sorted cell fraction.
MO-MDSC were sorted from splenocytes of tumour-bearing mice and cultured with 0.5mgml
 1 M-CSF. The expression of F4/80, MHCII, CD206 and
Gr-1 were measured on consecutive days.
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sdo not have a dominant role in our tumour models. Most
investigations are carried out in tumours with high metastasis
rates in combination with other therapeutic approaches (like
adjuvant endocrine therapy) (Saad et al, 2002; Hiraga et al, 2004;
Gnant, 2009). In these tumours, metastasis may be the cause of
death, in contrast to our model. As TAMs do have an essential role
in metastasis, ZA may be beneficial in these types of tumours
(Allavena et al, 2008a). However, in both human studies and
animal models, survival is only marginally influenced by ZA, and
also in tumours with high metastases rates (Hiraga et al, 2004;
Stathopoulos et al, 2008; Pandya et al, 2010; Ottewell et al, 2010).
To study the effects of ZA on macrophages in the primary
tumour, dose levels are higher than clinically advised. Doses
selected for clinical trials were based on changes in bone
resorption markers (including serum COOH-terminal telopeptide
and urinary N-telopeptide/creatinine ratio) and preliminary
evidence of efficacy on skeletal-related events; however, no studies
were performed comparing dose–effect relations on the tumour
microenvironment. Although there are some concerns on side
effects caused by ZA at higher levels (Ibrahim et al, 2003),
additional studies are required to determine the safety and efficacy
of increased dosages for this new application.
In conclusion, our data show that daily administration of ZA in
tumour-bearing mice inhibits myeloid differentiation and shifts
the balance from M2 macrophage phenotype to M1 macrophage
phenotype. However, as a consequence the number of immature
myeloid cells remains high in the spleen and in the effusion fluid,
especially in the MO-MDSC population. This MO-MDSC popula-
tion was found to have an immunosuppressive effect to which
we ascribe the fact that survival was not improved with ZA in
our study.
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